Circulating tumor cells in neuroblastoma: Current status and future perspectives

Yang, Ran; Zheng, Shan; Dong, Rui

doi:10.1002/cam4.4893

Cited by 5 publications

(3 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike cell-free DNA or RNA, CTCs are short-lived tumor cells shed from primary or metastatic sites that contain comprehensive information on tumor status. CTCs thus are dynamic markers whose presence in blood could provide actionable information to guide neuroblastoma patient management ( 64 ). Using CCT2 as a marker for CTCs adds pertinent information on the potential for the detected CTCs to originate from an aggressive or invasive cancer.…”

Section: Discussionmentioning

confidence: 99%

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

et al. 2022

View full text Add to dashboard Cite

Chaperonin containing TCP1 (CCT/TRiC) is a multi-subunit protein folding complex that enables the cancer phenotype to emerge from the mutational landscape that drives oncogenesis. We and others linked increased expression of CCT subunits to advanced tumor stage and invasiveness that inversely correlates with cancer patient outcomes. In this study, we examined the expression of the second CCT subunit, CCT2, using genomic databases of adult and pediatric tumors and normal tissues, and found that it was highly expressed in pediatric cancers, showing a significant difference compared to normal tissues. Histologic staining confirmed that CCT subunits are highly expressed in tumor tissues, which was exemplified in neuroblastoma. Using two neuroblastoma cells, MYCN-amplified, IMR-32 cells, and non-amplified, SK-N-AS cells, we assessed baseline levels for CCT subunits and found expressions comparable to the highly invasive triple-negative breast cancer (TNBC) cell line, MDA-MB-231. Exogenous expression of CCT2 in both SK-N-AS and IMR-32 cells resulted in morphological changes, such as larger cell size and increased adherence, with significant increases in the CCT substrates, actin, and tubulin, as well as increased migration. Depletion of CCT2 reversed these effects and reduced cell viability. We evaluated CCT as a therapeutic target in IMR-32 cells by testing a novel peptide CCT inhibitor, CT20p. Treatment with CT20p induced cell death in these neuroblastoma cells. The use of CCT2 as a biological indicator for detection of neuroblastoma cells shed in blood was examined by spiking IMR-32 cells into human blood and using an anti-CCT2 antibody for the identification of spiked cancer cells with the CellSearch system. Results showed that using CCT2 for the detection of neuroblastoma cells in blood was more effective than the conventional approach of using epithelial markers like cytokeratins. CCT2 plays an essential role in promoting the invasive capacity of neuroblastoma cells and Frontiers in Oncology frontiersin.org 01

show abstract

Section: Discussionmentioning

confidence: 99%

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Compared to adult solid tumors, neuroblastoma has fewer mutations, which presents a unique advantage. Moreover, it is possible to use single-cell and CTC proteomics analysis, which may lead us to a new step attributable to the capacity to detect cells more likely to resist treatment (54).…”

Section: Future Perspectivesmentioning

confidence: 99%

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review

Alpuim Costa,

Gonçalves-Nobre,

Sampaio-Alves

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Neuroblastoma is the most frequently diagnosed cancer during the first year of life. This neoplasm originates from neural crest cells derived from the sympathetic nervous system, adrenal medulla, or paraspinal ganglia. The clinical presentation can vary from an asymptomatic mass to symptoms resulting from local invasion and/or spread of distant disease spread. The natural history of neuroblastoma is highly variable, ranging from relatively indolent biological behavior to a high-risk clinical phenotype with a dismal prognosis. Age, stage, and biological features are important prognostic risk stratification and treatment assignment prognostic factors. The multimodal therapy approach includes myeloablative chemotherapy, radiotherapy, immunotherapy, and aggressive surgical resection. Hyperbaric oxygen therapy (HBOT) has been proposed as a complementary measure to overcome tumor hypoxia, which is considered one of the hallmarks of this cancer treatment resistance. This article aims to review the relevant literature on the neuroblastoma pathophysiology, clinical presentation, and different biological and genetic profiles, and to discuss its management, focusing on HBOT.

show abstract

“…Neuroblastoma (NB) is one of the most common extracranial solid tumors in children and infants. NB occurs in approximately 25-50 cases per million and accounts for 10%-20% of pediatric malignancy deaths [1]. High-risk NB (HRNB) is diagnosed when MYCN amplification is greater than stage 1 or age ≥ 18 months with stage 4 disease.…”

Section: Introductionmentioning

confidence: 99%

STING agonist delivery by lipid calcium phosphate nanoparticles enhances immune activation for neuroblastoma

Bao¹,

Lu²,

Zhang³

et al. 2023

Acta Materia Medica

View full text Add to dashboard Cite

Neuroblastoma (NB) is a common solid tumor in children and infants, the formation and regression of which is closely linked to the tumor-host immune relationship. Stimulator of interferon genes (STING) agonists, particularly cyclic dinucleotide (CDN), have promising potential in NB therapy by generating innate and adaptive immune stimulation, thus leading to tumor control. CDN delivery in vivo is challenging due to the negative charge, hydrophilicity, and susceptibility to degradation by phosphodiesterase, which hinders the effectiveness of CDN. Thus, our study proposed four methods to load CDN into liposomes, using 2′,3′-cGAMP as the model drug. Lipid nanoparticles were prepared, followed by physicochemical characterization. Subsequently, cellular inhibition and immune stimulation were investigated. As a result, lipid calcium phosphate nanoparticles (LCP-NPs) possessed the highest encapsulation efficiency among the four preparation methods, with a diameter of 82.57±3.72 nm. LCP-NPs maintained size stability under refrigeration conditions at 4°C within 48 h. The surface of the liposome was positively charged. Compared to free cGAMP, LCP-NPs resulted in a slower release, enhanced cytotoxicity against tumor cells, greater activation of the cGAS-STING pathway, and increased expression of the immune factors. Taken together, these findings clearly demonstrated the effectiveness of the liposomal delivery system for cGAMP and provided a promising strategy for the treatment of NB.

show abstract

Circulating tumor cells in neuroblastoma: Current status and future perspectives

Cited by 5 publications

References 108 publications

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review

STING agonist delivery by lipid calcium phosphate nanoparticles enhances immune activation for neuroblastoma

Contact Info

Product

Resources

About